Biopharmaceutical CMO & CRO Market Analysis by Source (Non-Mammalian, Mammalian), by Service (Contract Research, Contract Manufacturing), by Products (Biosimilar, Biologics), and by Region – Forecast to 2026
- Additional information
- Enquire about
Biopharmaceutical CMO & CRO Market Analysis by Source (Non-Mammalian, Mammalian), by Service (Contract Research, Contract Manufacturing), by Products (Biosimilar, Biologics), and by Region - Forecast to 2026
The global biopharmaceutical CMO & CRO market size is expected to witness a CAGR of X.X% during the forecast period. Contract Manufacturing Organizations (CMO’s) and Contract Research Organizations (CRO’s) offer a wide array of benefits associated with biological assay development, large-scale manufacturing, preclinical/clinical research, clinical trial management, and commercialization. Conducting in-house research & manufacturing activities by pharmaceutical firms pose to be cost and labour intensive, thereby minimizing the overall profitability and exhausting of resources.
Globally, rising need for clinical research, biopharmaceutical manufacturing, patent filing & renewal, and drug standardizations are factors driving the biopharmaceutical CRO & CMO market. Most pharmaceutical and biotechnology firms are widely outsourcing R&D and manufacturing operations worldwide by leveraging their cost burden to third party and increasing their profitability. However, the contamination risk and product adulteration concerns in outsourcing and inadequate skilled scientist presence as per project requirement are expected to hinder the growth.
Major companies operating in the biopharmaceutical CMO & CRO market are GVK Biosciences Private Limited. (India), Syneos Health (U.S.), Pharmaron, Inc. (China), Dassault Systèmes SE (France), ICON plc (Ireland), Parexel International (U.S.), Charles River Laboratories, Inc. (U.S.), PPD, Inc. (U.S.), IQVIA (U.S.), and Laboratory Corporation (U.S.). Ongoing product developments, investment in R&D, improvement in clinical management process, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2017 to 2025. The biopharmaceutical CMO & CRO market report is categorized into the following segments and subsegments:
Biopharmaceutical CMO & CRO Market, By Source (Revenue, 2017-2026, USD Billion)
Biopharmaceutical CMO & CRO Market, By Service (Revenue, 2017-2026, USD Billion)
- Contract Research
- Inflammation & Immunology
- Contract Manufacturing
- Fill & Finish Operations
- Analytical & QC Testing
- Process Development
- Upstream Process Development
- Downstream Process Development
Biopharmaceutical CMO & CRO Market, By Products (Revenue, 2017-2026, USD Billion)
- Monoclonal Antibodies
- Antisense, RNAi, & Molecular Therapy
- Recombinant Proteins
Biopharmaceutical CMO & CRO Market, By Region (Revenue, 2017-2026, USD Billion)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Key questions addressed by the research report-
- What are the current market trends (2017 to 2020) and future market forecast from 2021 to 2026 for the market?
- What are the market dynamics and probable opportunities for market players during the forecast period?
- Initiatives undertaken my market players to address the COVID-19 impact to sustain in the competitive market.
- Which geographies have immense opportunities in different segments and sub-segments of the market?
- What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?